Sentences with phrase «mlv vaccine products»

You just read any vaccine product information, and you'll see it stated very clearly: «This vaccine is known to have a risk of creating a very severe neurologic reaction.»

The control may be an inactive substance (placebo) or some other vaccine product.

Trial participants who receive a vaccine product may develop HIV antibodies and show a reaction on antibody tests.

As the Global HIV Vaccine Product Manager for the US Army, Dr. Ake advances the development of HIV vaccine candidates in preclinical and early clinical studies.

Or, instead of a single new vaccine product being tested, researchers may invent a new vaccine strategy using new combinations of vaccines, or new ways of giving the injections.

Each company has contributed product candidates to the collaboration: Sanofi Pasteur will contribute HSV - 529, a clinical - stage replication - defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate.

• Vaccine products consist of preventive pediatric, adolescent, and adult vaccines, primarily administered at physician offices.

• Pharmaceutical: Human pharmaceutical and vaccine products marketed either directly by the company or through joint ventures.

It is focused on the development of preventive and therapeutic vaccine products and cancer drugs for patients with unmet medical needs.

These events relate primarily to settlement of VaxGen's obligations under its lease of facilities in South San Francisco, and to the potential award of a procurement contract to Emergent BioSolutions (NYSE: EBS) by the U.S. Government for which VaxGen is eligible to receive milestone and royalty payments in connection with Emergent BioSolutions» May 2008 acquisition of VaxGen's recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology.

VXGN has other potentially valuable assets, including a «a state - of - the - art biopharmaceutical manufacturing facility with a 1,000 - liter bioreactor that can be used to make cell culture or microbial biologic products» and rights to specified percentages of future net sales relating to its anthrax vaccine product candidate and related technology.

Under the terms of the sale of its assets and rights relating to its anthrax vaccine product candidate and related technology to Emergent BioSolutions Inc, (Emergent), Emergent may be obligated to pay VXGN up to an additional $ 7M in milestone payments, plus specified percentages of future net sales for 12.5 years beginning from the first commercial sale.

VXGN has other potentially valuable assets, including a «state - of - the - art biopharmaceutical manufacturing facility with a 1,000 - liter bioreactor that can be used to make cell culture or microbial biologic products» and rights to specified percentages of future net sales relating to its anthrax vaccine product candidate and related technology.

We follow the most up to date recommendations and use the highest quality vaccine products.

Is the veterinarian recommending all vaccines, just because there is a vaccine product available?

Amorphous basophilic deposits resembling vaccine product may be present.

[4] For example the World Small Animal Veterinary Association Guidelines for the Vaccination of Dogs and Cats state «we should aim to reduce the «vaccine load» on individual animals in order to minimize the potential for adverse reactions to vaccine products».

You should only allow vaccines to be given to your pet if you are satisfied the vaccine product has been properly handled and refrigerated from manufacturer to administration.

There have been suggestions that CPV - 2c presents challenges in terms of virulence, diagnostic testing, or vaccine efficacy — but so far, studies have shown that current vaccine products as well as diagnostic tests function similarly with CPV - 2c as with the other variants.

Spilled or mis - injected vaccine product should be thoroughly cleaned to avoid accidental ingestion.

Also according to Dr. Ford, there are some DVMs who would like to follow the new guidelines, but are concerned that vaccine product labels include text that reads «annual booster recommended.»

Another important omission in Ms Long's article is discussion about appropriate timing of puppy vaccination, with some vaccine product labels recommending a finish at 10 or 12 weeks (13), which is in conflict with the WSAVA recommendation for a finish around 14 - 16 weeks.

However, more than three years after publication of the APVMA's Position Statement, core vaccine products with an annual revaccination «recommendation» remain on the market, e.g. Virbac's Canigen DHA2P (11) and Boehringer Ingelheim's Protech C3 (12).

While international dog and cat vaccination guidelines warn that we should decrease companion animal vaccination, i.e. «we should aim to reduce the «vaccine load» on individual animals in order to minimize the potential for adverse reactions to vaccine products» [18], vaccination of humans is increasing at a startling rate.

The APVMA is the government regulator of veterinary vaccine products.

It is my strong suspicion that annual revaccination of dogs with core MLV vaccine products remains prevalent practice in Australia.

[3] The WSAVA Guidelines also warn «we should aim to reduce the «vaccine load» on individual animals in order to minimize the potential for adverse reactions to vaccine products».

Coordinated data compilation and comprehensive review and disposition of sterile injectable vaccine product.

Not exact matches

Our global portfolio includes medicines and vaccines as well as many of the world's best - known consumer health care products.

The Animal Health business discovers, develops, manufactures, and markets animal health products including antibiotics, anti-inflammatory, vaccines, fertility disorder treatments, and parasiticides for cattle, swine, horses, poultry, dogs, cats, and fish.

China now has numerous life science companies that serve its domestic market, providing greater access to medical products and facilitating the development of the country's first WHO - prequalified vaccine.

In short, Novavax's flu vaccine could be a really big deal if it can outperform Sanofi's product.

In the healthcare sector, where accurate temperature monitoring of blood, tissues, drugs and vaccines throughout the supply chain is critical to the delivery of high quality products to patients, our monitoring solutions provide data integrity and reporting for audit purposes.

For example, I recall that the first sentence of that particular site was that vaccine manufacturers don't list the ingredients of their product anywhere.

Francesca said: «Parents are always being told and reminded about vaccines and this product will take advantage of current communications to let them know all there is to know about the MMR vaccine.

NOAH is a member of HealthforAnimals, an organisation representing manufacturers of veterinary medicines, vaccines and other animal health products in both developed and developing countries across five continents.

Some Vaccine in Latest Recall Administered by Oneida County Health Department «Potency of Nasal Spray Vaccine in Question — Safety Not an Issue» The Oneida County Health Department's current supply of H1N1 flu vaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the departmenVaccine in Latest Recall Administered by Oneida County Health Department «Potency of Nasal Spray Vaccine in Question — Safety Not an Issue» The Oneida County Health Department's current supply of H1N1 flu vaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the departmenVaccine in Question — Safety Not an Issue» The Oneida County Health Department's current supply of H1N1 flu vaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the departmenvaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the department said.

«In the last few years, we've decided that it's probably not a good idea to produce [vaccines] in food products,» says Hugh Mason, an Arizona State University vaccine researcher who helped develop the first edible vaccine.

The first vaccine to receive the green light for human trials is a product from Pennsylvania - based Inovio Pharmaceuticals.

TenOever is already taking advice from researchers in the vaccine industry about the limitations of current products, such as FluMist, so that he can learn how to improve them.

Unlike any other vaccine designed for human use, this product would be a DNA vaccine that only contains a particular part of the pathogen (rather than a vaccine with an inactivated live or dead virus, for example).

A panel of scientists said there was no scientific justification for this large - scale trial of a single product and the money has now been handed to the National Institutes of Health to compare several vaccines instead.

It went too far beyond the court's ruling on DNA, critics claimed, by suggesting that other naturally derived products — including chemical compounds, vaccines, seeds, and antibodies — must be «significantly different» from anything found in nature or else be immediately tossed out as patent ineligible.

Yet vaccine companies have little incentive to build expensive new factories to make a product that will mostly be used once wild polio is gone — maybe in three years, maybe 10 — and then only for another five years or so.

Vaccine skeptics, especially those irate at her rejection when she was CDC director of theories that link vaccines and autism, argue that the move to Merck demonstrates her bias — since Gerberding will now be promoting the products she defended while in government.

After the European Medicines Agency's Committee for Medicinal Products for Human Use meeting 19 - 22 October, the agency recommended that everyone regardless of age receive two doses of the pandemic flu vaccines approved for use there.

FDA is implementing a new law that gives it the authority to regulate tobacco products, taking a key role in the approval of the planned H1N1 pandemic flu vaccine, revamping its food - safety approach, and trying to make the agency's workings more transparent.

In addition to growth problems with the virus, Hall noted that one vaccine maker is still making seasonal flu vaccine and has yet to switch over to production of the novel H1N1 product.

The European Union and Australia have also approved the vaccine, and a similar product to be manufactured by GlaxoSmithKline is in the works.

Supari's position all along has been that the evil drug companies will turn these viruses into vaccines, and then charge so much for their products that the poor countries the viruses came from will never be able to afford the life - saving products.